MRRS adds "Short Bowel Syndrome – Pipeline Review, H2 2016" latest studies, published in December 2016. It is a professional and in-depth study.

Summary
Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Short Bowel Syndrome – Pipeline Review, H2 2016, provides an overview of the Short Bowel Syndrome (Gastrointestinal) pipeline landscape.

Short bowel syndrome is a complex disease that occurs due to the physical loss or the loss of function of a portion of the small and/or large intestine. Symptoms include bloating, cramping, fatigue, heartburn, vomiting, weakness and diarrhea. Complications of short bowel syndrome include malnutrition, peptic ulcers, kidney stones and small intestinal bacterial overgrowth. Treatment includes vitamin and mineral supplements, antibiotics, proton pump inhibitors and bile-salt binders.

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Short Bowel Syndrome (Gastrointestinal).
– The pipeline guide reviews pipeline therapeutics for Short Bowel Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Short Bowel Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Short Bowel Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Short Bowel Syndrome (Gastrointestinal)

Table Of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Short Bowel Syndrome Overview 7
Therapeutics Development 8
Pipeline Products for Short Bowel Syndrome - Overview 8
Short Bowel Syndrome - Therapeutics under Development by Companies 9
Short Bowel Syndrome - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Short Bowel Syndrome - Products under Development by Companies 13
Short Bowel Syndrome - Companies Involved in Therapeutics Development 14
Ardelyx Inc 14
Naia Ltd 15
Nutrinia Ltd 16
OxThera AB 17
Sancilio & Company Inc 18
Shire Plc 19
Tasly Pharmaceutical Group Co Ltd 20
Zealand Pharma AS 21
Short Bowel Syndrome - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
glepaglutide - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
....

Browse Complete Report with TOC @
http://www.marketresearchreportstore.com/shop/short-bowel-syndrome-pipeline-review-h2-2016

Ask a sample and any further questions, please feel free to contact us:
Tel: +00-1-626-3463946 - U.S
Email: [email protected]
Web: http://www.marketresearchreportstore.com/

About Market Research Report Store
Since the establishment, Market Research Report Store has determined to take the online market research reports platform to the next level. With our passion and profession, we are designed to be the best among the bests.
Market Research Report Store is one of the most fast-growing and professional online platforms for industry reports, market reports, and professional surveys. Our collection covers more than 100 global markets. We have cooperated with leading publishers and consultant companies to offer the best market intelligence products to our clients with instant access to our database.